EXAS vs. SNN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and SNN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
EXAS is a standard domestic listing, while SNN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | EXAS | SNN |
|---|---|---|
| Company Name | Exact Sciences Corporation | Smith & Nephew plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 8.99 billion USD | 16.34 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | February 1, 2001 | November 16, 1999 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of EXAS and SNN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | SNN |
|---|---|---|
| 5-Day Price Return | 5.28% | 2.60% |
| 13-Week Price Return | -16.56% | 30.35% |
| 26-Week Price Return | -4.35% | 34.08% |
| 52-Week Price Return | -20.46% | 18.10% |
| Month-to-Date Return | 1.11% | 18.97% |
| Year-to-Date Return | -15.52% | 39.50% |
| 10-Day Avg. Volume | 3.49M | 3.24M |
| 3-Month Avg. Volume | 3.10M | 2.40M |
| 3-Month Volatility | 38.63% | 34.25% |
| Beta | 1.22 | 1.16 |
Profitability
Return on Equity (TTM)
EXAS
-38.37%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
EXAS has a negative Return on Equity of -38.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
SNN
9.09%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
SNN’s Return on Equity of 9.09% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
EXAS
-34.19%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
EXAS has a negative Net Profit Margin of -34.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
SNN
8.26%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
SNN’s Net Profit Margin of 8.26% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
EXAS
-34.49%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
EXAS has a negative Operating Profit Margin of -34.49%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
SNN
12.75%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
SNN’s Operating Profit Margin of 12.75% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EXAS | SNN |
|---|---|---|
| Return on Equity (TTM) | -38.37% | 9.09% |
| Return on Assets (TTM) | -16.63% | 4.67% |
| Net Profit Margin (TTM) | -34.19% | 8.26% |
| Operating Profit Margin (TTM) | -34.49% | 12.75% |
| Gross Profit Margin (TTM) | 68.19% | 70.04% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.89
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
EXAS’s Current Ratio of 2.89 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
SNN
3.00
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
SNN’s Current Ratio of 3.00 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.95
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
SNN
0.62
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
SNN’s Debt-to-Equity Ratio of 0.62 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
SNN
4.80
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
SNN’s Interest Coverage Ratio of 4.80 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXAS | SNN |
|---|---|---|
| Current Ratio (MRQ) | 2.89 | 3.00 |
| Quick Ratio (MRQ) | 2.32 | 1.40 |
| Debt-to-Equity Ratio (MRQ) | 0.95 | 0.62 |
| Interest Coverage Ratio (TTM) | -15.18 | 4.80 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
SNN
2.03%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.03%, SNN offers a more attractive income stream than most of its peers in the Health Care Equipment & Supplies industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
SNN
66.60%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
SNN’s Dividend Payout Ratio of 66.60% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | EXAS | SNN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.03% |
| Dividend Payout Ratio (TTM) | 0.00% | 66.60% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for EXAS is currently unavailable.
SNN
32.78
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
SNN’s P/E Ratio of 32.78 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
EXAS
2.92
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 2.92 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
SNN
2.71
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
SNN’s P/S Ratio of 2.71 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXAS
4.06
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
EXAS’s P/B Ratio of 4.06 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
SNN
2.38
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
SNN’s P/B Ratio of 2.38 is in the lower quartile for the Health Care Equipment & Supplies industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EXAS | SNN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 32.78 |
| Price-to-Sales Ratio (TTM) | 2.92 | 2.71 |
| Price-to-Book Ratio (MRQ) | 4.06 | 2.38 |
| Price-to-Free Cash Flow Ratio (TTM) | 68.70 | 20.20 |